Structural studies of poliovirus mutants that overcome receptor defects

Nature Structural Biology

Volumn 4, Issue 8, 1997, Pages 666-674

  Wien, Michelle W ^a,d   Curry, Stephen ^b,c   Filman, David J ^b   Hogle, James M ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; VIRUS RECEPTOR;

ARTICLE; CRYSTALLOGRAPHY; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS MORPHOLOGY; VIRUS MUTANT; VIRUS TRANSFORMATION;

CAPSID; CAPSID PROTEINS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PHENOTYPE; POLIOVIRUS; PROTEIN BINDING; RECEPTORS, VIRUS; VIRULENCE;

POLIOVIRUS;

EID: 0030845915     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb0897-666     Document Type: Article

References (51)

1. Hogle J.M., Chow M. & Filman D.J. Three-dimensional structure of poliovirus at 2,9 Å resolution. Science 229, 1358-1365 (1985).
2. Yeates T.O. et al. Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera. EMBO J. 10, 2331-2341 (1991).
3. Filman D.J. et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8, 1567-1579 (1989).
4. Smith T.J. et al. The site of attachment in human rhinovirus 14 for anti-viral agents that inhibit uncoating. Science 233, 1286-1293 (1986).
5. Badger J. et al. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. USA 85, 3304-3308 (1988).
6. Badger J., Minor I., Oliviera M.A., Smith T.J. & Rossmann M.G. Structural analysis of anti-viral agents that interact with the capsid of human rhinoviruses. Proteins 6, 1-19 (1989).
7. Kim K.H. et al. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J. Mol. Bio. 230, 206-227 (1993).
8. Grant R.A. et al. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr. Biol. 4, 784-797 (1994).
9. Hadfield A.T. et al. Structural studies on human rhinovirus 14 drug-resistant compensation mutants. J. Mol. Biol. 253, 61-73 (1995).
10. Hiremath C.N., Grant R.A., Filman D.J. & Hogle J.M. Binding of the Antiviral Drug WIN517 to the Sabin Strain of Type 3 Poliovirus: Structural Comparison with Drug Binding in Rhinovirus 14. Acta Crystallogr. D D51, 473-189 (1995).
11. Mendelsohn C., Wimmer E. & Racaniello V.R. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin super-family. Cell 56, 855-865 (1989).
12. Mason P.W. et al. Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor Virology 192, 568-577 (1993).
13. Racaniello V.R. The poliovirus receptor: a hook, or an unzipper? Structure 4, 769-773 (1996).
14. Wien M.W., Chow M. & Hogle J.M. Poliovirus: new insights from an old paradigm. Structure 4, 763-767 (1996).
15. Fricks C.E. & Hogle J.M. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64, 1934-1945 (1990).
16. Wetz K. & Kuciniski T. Influence of different ionic and pH environments on structural alterations of poliovirus and their possible relation to virus uncoating. J. Gen. Virology 72, 2541-2544 (1991).
17. Curry S., Chow M. & Hogle J.M. The poliovirus 1355 particle is infectious. J. Virol. 70, 7125-7131 (1996).
18. Li Q., Yafal A.G., Lee Y.M.-H., Hogle J.M. & Chow M. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperatures. J. Virol. 68, 3965-3970 (1994).
19. Caliguiri L.A., McSharry J.J. & Lawrence G.W. Effect of arildone on modifications of poliovirus in vitro. Virology 105, 86-93 (1980).
20. Everaert L., Vrijsen R. & Boeyé A. Eclipse products of poliovirus after cold-synchronized infection of HeLa cells. Virology 171, 76-82 (1989).
21. McSharry J.J., Galiguiri L.A. & Eggers H.J. Inhibition of uncoating of poliovirus, a new antiviral drug. Virology 97, 307-315 (1979).
22. Ofori-Anyinam O., Vrijsen R., Kronenberger P. & Boeyé A. Effect of a capsid-stabilizing pyridazinameine, R78206, on the eclipse and intracellular location of poliovirus. J. Virol. 67, 2367-2369 (1993).
23. Zeichhardt H., Otto M.J., McKinlay M.A., Willingmann P. & Habermehl K.-O. Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology 160, 281-285 (1987).
24. Morrison M.E., He Y.J., Wien M.W., Hogle J.M. & Racaniello V.R. Homolog-scanning mutagenesis reveals poliovirus receptor residues important for virus binding and replication. J. Virol. 66, 2807-2813 (1994).
25. Colston E.M. & Racaniello V.R. Poliovirus variants selected on mutant receptor-expressing cells identify residues that expand receptor recognition. J. Virol. 69, 4823-4829 (1995).
26. Aoki J., Koike S., Ise I., Sato-Yoshida Y. & Nomoto A. Amino acid residues on human poliovirus receptor involved in interaction with poliovirus. J. Biol. Chem. 269, 8431-8438 (1994).
27. Bernhardt G., Harber J., Zibert A., DeCrombrugghe M. & Wimmer E. The poliovirus receptor: Identification of domains and amino acid residues critical for virus binding. Virology 203, 344-356 (1994).
28. Harber J., Bernhardt G., Lu H.-H., Sgro J.-Y. & Wimmer E. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214, 559-570 (1995).
29. Colston E.M. & Racaniello V.R. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 13, 5855-5862 (1994).
30. Evans D.J. & Almond J.W. Design, construction and characterization of poliovirus antigen chimeras. Meths. Enz. 203, 385-400 (1991).
31. Moss E.G. & Racaniello V.R. Host range determinants located on the interior of the poliovirus capsid. EMBO J. 10, 1067-1074 (1991).
32. Martin A. et al. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimeric virus which is neurovirulent in mice. EMBO J. 7, 2839-2847 (1988).
33. Martin A. et al. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180, 648-658 (1991).
34. Matthews B.W. Structural and genetic analysis of the folding and function of T4 lysozyme. FASEB J. 10, 35-41 (1996).
35. Grant R.A., Filman D.J., Fujinami R.S., Icenogle J.P. & Hogle J.M. Three-dimensional structure of Theiler virus. Proc. Natl. Acad. Sci. USA 89, 2061-2065 (1992).
36. Chow M., Basavappa R. & Hogle J.M. In The structure of viruses; (Eds., Chiu, W., Garcea, R. & Burnette, R.) (Oxford University Press, Oxford; 1997).
37. Palmenberg A.C. In Molecular Aspects of Picornaviral Infection and Detection; (Eds., Semler, B. I. & Ehrenfeld, E.) 211-242 (American Society for Microbiology, Washington, D.C.; 1989).
38. Couderc T. et al. Analysis of neutralization-escape mutant selected from a mouse virulent type1/type2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted. J. Gen. Virology 973-977 (1991).
39. Pavio N., Buc-Caron M.-H. & Colbere-Garapin F. Persistent poliovirus infection of human fetal brain cells. J. Virol. 70, 6395-6401 (1996).
40. Couderc T. et al. Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice. J. Virol. 68, 8386-8391 (1994).
41. Dermody T.S., Nibert M.L., Wetzel J.D., Tong X. & Fields B.N. Cells and viruses with mutations affecting viral entry are selected during persistent infections of L cells with mammalian reoviruses. J. Virol. 67, 2055-2063 (1993).
42. Calvez V. et al. Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants. Virology 212, 309-322 (1995).
43. Couderc T., Delpeyroux F., Le Blay H. & Blondel B. Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating. J. Virol. 70, 305-312 (1996).
44. Rodgers D.W. Cryotrystallography. Structure 2, 1135-1140 (1994).
45. Otwinowski Z. In Data collection and processing; (Eds., Sawyer, L., Isaacs, N. & Bailey, S.) 80-86 (SERC Darsbury Laboratory, Warrington; 1993).
46. Bricogne G. Acta Crystallographica A30, 395-405 (1974).
47. Jacobson D.H., Hogle J.M. & Filman D.J. A pseudo-cell based approach to efficient crystallographic refinement of viruses. Acta Crystallogr. D D52, 693-711 (1996).
48. Brünger A.T. X-PLOR Manual, Version 3.1; Yale University: New Haven, CT (1992).
49. Jones A.T. Interactive computer graphics: FRODO. Meths. Enz. 115, 157-171 (1985).
50. Kraulis P.J. Molscript: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950 (1991).
51. Evans S.V. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graphics 11, 134-138 (1990).